Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB
Demand Analysis for GLP-1 Nutritional Support Market in China The China market rose from approximately 10.8% in 2020 to 2024 to 15.4% during 2025 to 2035, fueled by government-led metabolic health programs and expansion in GLP-1 drug coverage
17 However, Novo Nordisk has listed over 20 patents for Ozempic, many of which focus on the injection device and do not expire until the late 2030s
Gastrointestinal adverse events were predominantly limited to initial dosing, while dose escalation resulted in lower discontinuation rates owing to these adverse events than among patients who remained on the starting dose
"Without addressing the underlying causes [of obesity ] whether through lifestyle changes, behavioral interventions, or personalized treatment weight loss may not be sustainable, explains Andres Acosta, MD, PhD , associate professor of medicine at Mayo Clinic